18F-FLT-PET in Breast Cancer (MK-0000-139)

A Pilot Study to Evaluate the Correlation Between 18F-FLT-PET Uptake, Ki-67 Immunohistochemistry, and Proliferation Signature in Response to Neo-Adjuvant Chemotherapy in Breast Cancer

This study correlated changes from baseline in Ki-67, an immunohistochemical marker of cell proliferation, with changes from baseline in tumor uptake of 3'-deoxy-3'[18F]-fluorothymidine (18F-FLT) following the first cycle of treatment with standard of care neo-adjuvant therapy in participants with breast cancer.

Inclusion Criteria:

• Has newly-diagnosed stage IIB/IIIA/IIIB locally advanced breast cancer
• Is eligible for pre-operative (neo-adjuvant) chemotherapy

Exclusion Criteria:

• Has a contraindication to magnetic resonance imaging (MRI)
• Any condition that would limit ability to undergo MRI or PET scans
• Is a nursing mother
• Has moderate to end-stage renal disease and is not on dialysis or has renal failure on chronic dialysis